BioCentury | Oct 26, 2020
Emerging Company Profile

Serial dealmaker Glick to lead cancer start-up Scorpion with familiar VCs supplying $108M

A VC syndicate that backed IFM and serial dealmaker Gary Glick has launched precision oncology start-up Scorpion, where Glick will be president and CEO, with $108 million in series A funding. Scorpion...
BioCentury | Oct 17, 2020

Novartis Venture Fund’s move to earlier, riskier bets starting to pay off

Over the last three and a half years, Novartis Venture Fund has remade its team and narrowed its remit to early-stage opportunities in therapeutics. The fund’s 2020 exits suggest the strategic shift may...
BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

The most recent Phase III data from a heart failure candidate may have been underwhelming, but a look at the broader pipeline suggests the long period of drought in innovation could soon give way to...
BioCentury | Sep 24, 2020

Data Bytes: record fund for Longitude follows rush of deals, IPOs

On the back of seven liquidity events in the past four months, Longitude Capital has closed its largest fund to date at $585 million. Managing Director Patrick Enright told BioCentury Longitude Venture Partners IV will...
BioCentury | Sep 24, 2020
Product Development

The road ahead for the tau hypothesis of Alzheimer’s disease

The Phase II miss of the first tau antibody to reach that stage continue the tradition in Alzheimer’s disease of bad news with hard-to-interpret ramifications for the target. At a minimum, the data call into...
BioCentury | Sep 22, 2020

Next up, NodThera? Roche’s €380M deal for Inflazome is latest NLRP3 takeout

With its €380 million takeout of Dublin-based Inflazome, Roche is continuing the rush of pharmas targeting inflammasome companies in a deal that leaves NodThera as the last company standing among the first crop of high...
BioCentury | Jun 4, 2020

NodThera parlays interest in inflammasome into Novo Ventures-led $55M series B

Novo Ventures has led a $55 million series B round for NodThera, a trans-Atlantic biotech operating in an area ripe for takeouts -- the inflammasome. The biotech's lead program targets NLRP3, a target explored by...
BioCentury | May 6, 2020
Emerging Company Profile

Ventus: A structural edge in innate immunity targets

Ventus emerged from stealth on Wednesday with a Versant-led $60 million series A round and a drug discovery platform designed to tackle one of the biggest challenges of targeting innate immune signaling: the lack of...
BioCentury | Apr 25, 2020

Novartis business development stays on course during COVID-19

Even if COVID-19 does disrupt operations or create a buyer’s market, Novartis will not veer from its business development strategy. The pharma was already expanding external innovation before the crisis, and has no intention of...
BioCentury | Jan 28, 2020
Company News

Quenching the flames of inflammatory cell death

Emerging from stealth Monday with a $50 million A round, Quench Bio is targeting the nexus of inflammatory cell death. RA Capital led the round with participation from new investor AbbVie Ventures. Atlas Venture and...
Items per page:
1 - 10 of 93